Letters sent to healthcare professionals in March 2018

Letters were sent to healthcare professionals about Zinbryta▼ (daclizumab beta), Lynparza 50 mg capsules, and radium-223-dichloride (Xofigo▼).

• From: Medicines and Healthcare products Regulatory Agency
• Published: 24 April 2018

• Therapeutic area: Cancer, Haematology and Neurology

In March 2018, letters were sent to healthcare professionals about:

• Zinbryta▼ (daclizumab beta): Marketing authorisation suspended in the European Union – for more information see Drug Safety Update, March 2018
• Recall of specific batches of Lynparza 50 mg capsules
• Radium-223-dichloride (Xofigo▼) contraindicated in combination with abiraterone acetate (Zytiga) and prednisolone/prednisone – for more information see Drug Safety Update, December 2017

Article citation: Drug Safety Update volume 11 issue 9; April 2018: 4.

Published 24 April 2018